Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patient’s lives depend on it. We imagine a world where cancer is a curable disease.
At Replimune, we live by our values:
United: We Collaborate for a Common Goal.
Audacious: We Are Bold and Innovative.
Dedicated: We Give Our Full Commitment.
Candid: We Are Honest With Each Other.
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, an innovative and collaborative culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to contribute to the meaningful work we do which could impact the lives of patients, caregivers and themselves.
Join us, as we reshape the future.
The Director of HCP Marketing will play a leading role in developing the commercial efforts for Replimune’s first product, RP1. Working closely with the Executive Director of Marketing, this role is responsible for creating and executing the vision, strategic, and tactical marketing plans for RP1 in PD-1 failed Melanoma. He/she will help build the campaign and launch plan to ensure commercial success for RP1. As a member of a small and agile commercial team, this role will work across the organization to ensure commercial and company success.
This position will be based out of our Woburn office.
Educational Requirements:
Bachelor's Degree; MBA or advanced degree preferred. Equivalent life science career experience would be accepted.
Required Experience:
Location Requirement:
This position is based in our Woburn office and welcomes hybrid work! Local candidates are expected to be on-site 2 days per week.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.
Replimune is an equal opportunity employer.
Software Powered by iCIMS
www.icims.com